Thyroid hormone analogues for the treatment of metabolic disorders: New potential for unmet clinical needs?

Endocrine Practice

Volumn 18, Issue 6, 2012, Pages 954-964

  Shoemaker, Timothy J ^a   Kono, Tatsuyoshi ^a   Mariash, Cary N ^a,c   Evans Molina, Carmella ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

^c METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; EPROTIROME; GC 24; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KB 141; LIOTHYRONINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MB 07344; MB 07811; N [4 [3 [(4 FLUOROPHENYL)HYDROXYMETHYL] 4 HYDROXYPHENOXY] 3,5 DIMETHYLPHENYL]MALONAMIC ACID; PLACEBO; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR BETA; THYROID HORMONE RECEPTOR BETA AGONIST; THYROXINE; TRIAC 3,5 DIIODOTHYROPROPIONIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD PRESSURE; BODY FAT; BODY WEIGHT; CHOLESTEROL TRANSPORT; DRUG DESIGN; DRUG EFFICACY; ENERGY METABOLISM; GENE EXPRESSION; GENE MUTATION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEART RATE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERMETABOLISM; LIOTHYRONINE BLOOD LEVEL; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THYROXINE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; HYPERLIPIDEMIAS; METABOLIC DISEASES; MICE; OBESITY; THYROID HORMONE RECEPTORS BETA;

EID: 84871386807     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12086.RA     Document Type: Review

References (105)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. www.cdc.gov/diabetes/pubs/pdf/ ndfs-2011.pdf. Accessed for verification July 19, 2012.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303: 235-241.
3. American Diabetes Association. 2011 National Diabetes Fact Sheet. http://www.diabetes.org/diabetes-basics/diabetes-statistics/?loc= DropDownDB-stats. Accessed for verification July 19, 2012.
4. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompason TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 2006; 29: 2114-2116.
5. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003; 290: 1884-1890.
6. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010; 121: 586-613.
7. American Heart Association. Conditions associated with Coronary Heart Disease. http://www.heart.org/HEARTORG/Conditions/Conditions-UCM-001087- SubHomePage.jsp. Accessed for verification July 19, 2012.
8. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [published correction appears in Am J Cardiol. 1998; 82: 128]. Am J Cardiol. 1998; 81: 582-587.
9. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160: 459-467.
10. Jukema JW, Chiang CW, Ferrières J, et al. Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. Curr Med Res Opin. 2010; 26: 2589-2597.
11. Atar D, Ong S, Lansberg PJ. Expanding the evidence base: comparing randomized controlled trials and observational studies of statins. Am J Ther. 2012 [Epub ahead of print].
12. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011; 34(suppl 1): S11-S61.
13. Vouri SM, Shaw RF, Waterbury NV, Egge JA, Alexander B. Prevalence of achievement of A1c, blood pressure, and cholesterol (ABC) goal in veterans with diabetes. J Manag Care Pharm. 2011; 17: 304-312.
14. Bertoni AG, Clark JM, Feeney P, et al. Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complications. 2008; 22: 1-9.
15. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007; 298: 2028-2037.
16. Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther. 2011; 90: 40-51.
17. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011; 365: 1597-1604.
18. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010; 31: 139-170.
19. Greenspan, FS. The Thyroid Gland. In: Greenspan FS, Gardner DG, eds. Basic and Clinical Endocrinology. 7th ed. New York, NY: Lange Medical Books/McGraw Hill, 2004: 215-294.
20. Laurberg P. Mechanisms governing the relative proportions of thyroxine and 3, 5, 3′-triiodothyronine in thyroid secretion. Metabolism. 1984; 33: 379-392.
21. Abel ED, Boers ME, Pazos-Moura C, et al. Divergent roles for thyroid hormone receptor beta isoforms in the endocrine axis and auditory system. J Clin Invest. 1999; 104: 291-300.
22. Harvey CB, Williams GR. Mechanism of thyroid hormone action. Thyroid. 2002; 12: 441-446.
23. O'Shea PJ, Harvey CB, Suzuki H, et al. A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone. Mol Endocrinol. 2003; 17: 1410-1424.
24. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000; 132: 270-278.
25. Mason RL, Hunt HM, Hurxthal L. Blood cholesterol values in hyperthyroidism and hypothyroidism-their significance. N Engl J Med. 1930; 203: 1273-1278.
26. Galioni EF, Gofman JW, Guzvich P, Pouteau J, Rubinger JH, Strisower B. Long-term effect of dried thyroid on serum-lipoprotein and serum-cholesterol levels. Lancet. 1957; 272: 120-123.
27. Gofman JW, Jones HB, Lindgren FT, Lyon TP, Elliott HA, Strisower B. Blood lipids and human atherosclerosis. Circulation. 1950; 2: 161-178.
28. Strisower B, Gofman JW, Galioni E, Rubinger JH, O'Brien GW, Simon A. Effect of long-term administration of desiccated thyroid on serum lipoprotein and cholesterol levels. J Clin Endocrinol Metab. 1955; 15: 73-80.
29. Strisower B, Gofman JW, Galioni EF, Almada AA, Simon A. Effect of thyroid extract on serum lipoproteins and serum cholesterol. Metabolism. 1954; 3: 218-227.
30. Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol. 2010; 4: 483-490.
31. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004; 5: 81-87.
32. Deedwania PC, Hunninghake DB, Bays HE, Jone PH, Cain VA, Blasetto JW. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005; 95: 360-366.
33. Erion MD, Cable EE, Ito BR, et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A. 2007; 104: 15490-15495.
34. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010; 362: 906-916.
35. Fujino A, Watanabe T, Kunii H, et al. Lipoprotein(a) is a potential coronary risk factor. Jpn Circ J. 2000; 64: 51-56.
36. Pedrelli M, Pramfalk C, Parini P. Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport. World J Gastroenterol. 2010; 16: 5958-5964.
37. Hargrove GM, Junco A, Wong NC. Hormonal regulation of apolipoprotein AI. J Mol Endocrinol. 1999; 22: 103-111.
38. Johansson L, Rudling M, Scanlan TS, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci U S A. 2005; 102: 10297-10302.
39. Trost SU, Swanson E, Gloss B, et al. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology. 2000; 141: 3057-3064.
40. Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3, 5, 3′-triiodo-L-thyronine. Endocrinology. 2004; 145: 1656-1661.
41. Lin VH, Klepp HM, Hanley RM. Sobetirome is a TR- and liver selective thyromimetic that can effect substantial LDL-C lowering without significant changes in heart rate or the thyroid axis in euthyroid men. Presented at the 90th Annual Meeting of The Endocrine Society, June 15-18, 2008; San Francisco, California.
42. Goldman S, McCarren M, Morkin E, et al. DITPA (3, 5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation. 2009; 119: 3093-3100.
43. Berkenstam A, Kristensen J, Mellström K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A. 2008; 105: 663-667.
44. Bryzgalova G, Effendic S, Khan A, et al. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB141. J Steroid Biochem Mol Biol. 2008; 111: 262-267.
45. Grover GJ, Mellström K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A. 2003; 100: 10067-10072.
46. Tancevski I, Demetz E, Eller P, et al. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One. 2010; 5: e8722.
47. Tancevski I, Wehinger A, Demetz E, et al. The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res. 2009; 50: 938-944.
48. Ladenson PW, McCarren M, Morkin E, et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab. 2010; 95: 1349-1354.
49. Raval S. Diiodothyropropionic acid: WO2008106213. Expert Opin Ther Pat. 2010; 20: 593-596.
50. Villicev CM, Freitas FR, Aoki MS, et al. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol. 2007; 193: 21-29.
51. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev. 1993; 14: 348-399.
52. Wikström L, Johansson C, Saltó C, et al. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J. 1998; 17: 455-461.
53. Forrest D, Hanebuth E, Smeyne RJ, et al. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function. EMBO J. 1996; 15: 3006-3015.
54. Bassett JH, Nordström K, Boyde A, et al. Thyroid status during skeletal development determines adult bone structure and mineralization. Mol Endocrinol. 2007; 21: 1893-1904.
55. Bassett JH, Williams GR. The skeletal phenotypes of TRalpha and TRbeta mutant mice. J Mol Endocrinol. 2009; 42: 269-282.
56. Rivkees SA, Bode HH, Crawford JD. Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature. N Engl J Med. 1988; 318: 599-602.
57. Segni M, Gorman CA. The aftermath of childhood hyperthyroidism. J Pediatr Endocrinol Metab. 2001; 14(suppl 5): 1277-1282.
58. El Hadidy ME, Ghonaim M, El Gawad SS, El Atta MA. Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men. BMC Endocr Disord. 2011; 11: 15.
59. Coronary Drug Project Research Group. The coronary drug project: findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA. 1972; 220: 996-1008.
60. Oppenheimer JH, Schwartz HL. Stereospecific transport of triiodothyronine from plasma to cytosol and from cytosol to nucleus in rat liver, kidney, brain, and heart. J Clin Invest. 1985; 75: 147-154.
61. Schwartz HL, Trence D, Oppenheimer JH, Jiang NS, Jump DB. Distribution and metabolism of L- and D-triiodothyronine (T3) in the rat: preferential accumulation of L-T3 by hepatic and cardiac nuclei as a probable explanation of the differential biological potency of T3 enantiomers. Endocrinology. 1983; 113: 1236-1243.
62. Young WF Jr, Gorman CA, Jiang NS, Machacek D, Hay ID. L-thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect. Clin Pharmacol Ther. 1984; 36: 781-787.
63. Bommer C, Werle E, Walter-Sack I, et al. D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. J Am Soc Nephrol. 1998; 9: 90-96.
64. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F. Metabolic effects of thyroid hormone derivatives. Thyroid. 2008; 18: 239-253.
65. Koury EJ, Pawlyk AC, Berrodin TJ, Smolenski CL, Nagpal S, Deecher DC. Characterization of ligands for thyroid receptor subtypes and their interactions with co-regulators. Steroids. 2009; 74: 270-276.
66. Sherman SI, Ringel MD, Smith Mj, Kopelen HA, Zoghbi WA, Ladenson PW. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab. 1997; 82: 2153-2158.
67. Rowe GG, Huston JH, Weinstein AB, Tuchman H, Brown JF, Crumpton CW. The hemodynamics of thyrotoxicosis in man with special reference to coronary blood flow and myocardial oxygen metabolism. J Clin Invest. 1956; 35: 272-276.
68. Humerfelt S, Muller O, Storstein O. The circulation in hyperthyroidism: a cardiac catheterization study before and after treatment. Am Heart J. 1958; 56: 87-94.
69. Graettinger JS, Muenster JJ, Selverstone LA, Campbell JA. A correlation of clinical and hemodynamic studies in patients with hyperthyroidism with and without congestive heart failure. J Clin Invest. 1959; 38: 1316-1327.
70. Pennock GD, Raya TE, Bahl JJ, Goldman S, Morkin E. Cardiac effects of 3, 5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther. 1992; 263: 163-169.
71. U.S. National Institutes of Health, Clinical Trials.gov. http://clinicaltrials.gov/ct2/search. Accessed July 19, 2012.
72. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ. A structural role for hormone in the thyroid hormone receptor. Nature. 1995; 378: 690-697.
73. Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC, Scanlon TS. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol. 1998; 5: 299-306.
74. Danzi S, Klein I. Cardiac specific effects of thyroid hormone analogues. Horm Metab Res. 2011; 43: 737-742.
75. Shiohara H, Nakamura T, Kikuchi N, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor b (TRb) agonists for the treatment of dyslipidemia. Bioorg Med Chem. 2012; 20: 3622-3634.
76. Erion MD, Reddy KR, Boyer SH, et al. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J Am Chem Soc. 2004; 126: 5154-5163.
77. Martinez L, Nascimento AS, Nunes FM, et al. Gaining ligand selectivity in thyroid hormone receptors via entropy. Proc Natl Acad Sci U S A. 2009; 106: 20717-20722.
78. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009; 8: 308-320.
79. QUATRx. Clinical Portfolio: Developing new therapies for endocrine, metabolic, and cardiovascular diseases. http://www.quatrx.com/clinical/index. htm. Accessed for verification July 19, 2012.
80. FierceBiotech. Metabasis therapeutics announces the publication of pre-clinical findings on MB07811, its product candidate. http://www. fiercebiotech.com/press-releases/metabasis-therapeutics-announces-publication- pre-clinical-findings-mb07811-its-produc. Accessed for verification July 19, 2012.
81. Ito BR, Zhang BH, Cable EE, et al. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol. 2009; 156: 454-465.
82. Ligand Pharmaceuticals. Ligand Pipeline. http://www.ligand.com/pipeline. Accessed for verification July 19, 2012.
83. Karo Bio. Karo Bio terminates the eprotirome program. http://www.karobio.com. Accessed for verification July 19, 2012.
84. Silva JE. Thyroid hormone control of thermogenesis and energy balance. Thyroid. 1995; 5: 481-492.
85. Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes. 2010; 17: 408-413.
86. Ribeiro MO, Carvalho SD, Schultz JJ, et al. Thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific. J Clin Invest. 2001; 108: 97-105.
87. Bratusch-Marrain P, Schmid P, Waldhäusl W, Schlick W. Specific weight loss in hyperthyroidism. Horm Metab Res. 1978; 10: 412-415.
88. van Hardeveld C, Kassenaar AA. Influence of experimental hyperthyroidism on skeletal muscle metabolism in the rat. Acta Endocrinol (Copenh). 1977; 85: 71-83.
89. Celi FS, Zemskova M, Linderman JD, et al. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab. 2011; 96: 3466-3474.
90. Marrif H, Schifman A, Stepanyan Z, et al. Temperature homeostasis in transgenic mice lacking thyroid hormone receptor-alpha gene products. Endocrinology. 2005; 146: 2872-2884.
91. Freitas FR, Moriscot AS, Jorgetti V, et al. Spared bone mass in rats treated with thyroid hormone receptor TR beta-selective compound GC-1. Am J Physiol Endocrinol Metab. 2003; 285: E1135-E1141.
92. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999; 115: 836-847.
93. Amorim BS, Ueta CB, Freitas BC, et al. A TRbeta-selective agonist confers resistance to diet-induced obesity. J Endocrinol. 2009; 203: 291-299.
94. Holness MJ, Greenwood GK, Smith ND, Sugden MC. PPARalpha activation and increased dietary lipid oppose thyroid hormone signaling and rescue impaired glucose-stimulated insulin secretion in hyperthyroidism. Am J Physiol Endocrinol Metab. 2008; 295: E1380-E1389.
95. Holness MJ, Sugden MC. Continued glucose output after re-feeding contributes to glucose intolerance in hyperthyroidism. Biochem J. 1987; 247: 801-804.
96. Mitrou P, Raptis SA, Dimitriadis G. Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr Rev. 2010; 31: 663-679.
97. Menahan LA, Wieland O. The role of thyroid function in the metabolism of perfused rat liver with particular reference to gluconeogenesis. Eur J Biochem. 1969; 10: 188-194.
98. Böttger I, Kriegel H, Wieland O. Fluctuation of hepatic enzymes important in glucose metabolism in relation to thyroid function. Eur J Biochem. 1970; 13: 253-257.
99. Müller MJ, Seitz HJ. Thyroid hormone action on intermediary metabolism: Part I; respiration, thermogenesis and carbohydrate metabolism. Klin Wochenschr. 1984; 62: 11-18.
100. Lenzen S, Joost HG, Hasselblatt A. The inhibition of insulin secretion from the perfused rat pancreas after thyroxine treatment. Diabetologia. 1976; 12: 495-500.
101. Lenzen S. Dose-response studies on the inhibitory effect of thyroid hormones on insulin secretion in the rat. Metabolism. 1978; 27: 81-88.
102. Wajchenberg BL, Cesar FP, Leme CE, Souza IT, Pieroni RR, Mattar E. Carbohydrate metabolism in thyrotoxicosis: studies on insulin secretion before and after remission from the hyperthyroid state. Horm Metab Res. 1978; 10: 294-299.
103. Verga Falzacappa C, Mangialardo C, Raffa S, et al. The thyroid hormone T3 improves function and survival of rat pancreatic islets during in vitro culture. Islets. 2010; 2: 96-103.
104. Verga Falzacappa C, Patriarca V, Bucci B, et al. The TRbeta1 is essential in mediating T3 action on Akt pathway in human pancreatic insulinoma cells. J Cell Biochem. 2009; 106: 835-848.
105. Verga Falzacappa C, Mangialardo C, Madaro L, et al. Thyroid hormone T3 counteracts STZ induced diabetes in mouse. PLoS One. 2011; 6: e19839.